a Groningen Research Institute of Pharmacy , Unit of PharmacoTherapy, Epidemiology & Economics , University of Groningen , The Netherlands.
b Department of Clinical Pharmacy and Toxicology , Martini Hospital , Groningen , The Netherlands.
Curr Med Res Opin. 2018 Oct;34(10):1839-1847. doi: 10.1080/03007995.2018.1459528. Epub 2018 May 3.
There is limited evidence on patients' adherence and the impact of the prescribed dosing regimen in non-vitamin-K oral anticoagulants (NOACs). We aimed to assess secondary adherence to NOACs and to determine the impact of the dosing regimen in patients with atrial fibrillation.
Patients using a NOAC between 2009 and 2013 were identified from the nation-wide Swedish Prescribed Drug Register and the Dutch regional IADB.nl database. Patients using a consistent dosage for at least 180 consecutive days were included. Adherence was calculated using the medication possession ratio (MPR) and adjusted for overlapping dates. Adherence was defined as a MPR ≥0.8. Sensitivity analyses were performed using a MPR ≥0.9. Logistic regression was performed to compare secondary adherence and to explore the influence of the dosing regimen.
A total of 5254 Swedish and 430 Dutch NOAC users were included. The mean MPR was 96.0% (SD 7.8%) in Sweden and 95.1% (SD 10.1%) in the Netherlands. Multivariable logistic regression analysis showed that a twice daily regimen had a lower likelihood of being secondary adherent compared to a once daily regimen in Sweden (odds ratio [OR] 0.21 [95% CI 0.12-0.35]).
The influence of selection bias introduced by the inclusion criterion of ≥2 dispensations covering at least 180 days could not be excluded.
This study demonstrated that secondary adherence was high in this specific setting among patients with at least two initial dispensations of a NOAC covering a minimum of 180 days. The use of NOACs in a once daily regimen showed higher adherence compared to a twice daily regimen.
关于非维生素 K 口服抗凝剂(NOAC)患者的依从性和规定剂量方案的影响,证据有限。我们旨在评估 NOAC 的二级依从性,并确定房颤患者剂量方案的影响。
从全国性瑞典处方药物登记处和荷兰区域性 IADB.nl 数据库中确定了 2009 年至 2013 年期间使用 NOAC 的患者。纳入了至少连续 180 天使用稳定剂量的患者。使用药物持有率(MPR)计算依从性,并针对重叠日期进行调整。依从性定义为 MPR≥0.8。使用 MPR≥0.9 进行敏感性分析。进行逻辑回归以比较二级依从性并探索剂量方案的影响。
共纳入了 5254 名瑞典和 430 名荷兰的 NOAC 使用者。瑞典的平均 MPR 为 96.0%(SD 7.8%),荷兰为 95.1%(SD 10.1%)。多变量逻辑回归分析表明,与每日一次方案相比,每日两次方案在瑞典二次依从的可能性较低(比值比[OR] 0.21[95%CI 0.12-0.35])。
不能排除纳入至少两次初始剂量覆盖至少 180 天的纳入标准引入的选择偏差的影响。
本研究表明,在至少两次初始剂量覆盖至少 180 天的特定环境中,NOAC 的二次依从性较高。与每日两次方案相比,每日一次方案使用 NOAC 具有更高的依从性。